Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include very common findings: Ptosis, Ophthalmoparesis, Ophthalmoplegia, and Global developmental delay and others; and common findings: Myopia and Facial palsy. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Intellectual disability, Global developmental delay, Specific learning disability |
Biomarker and diagnostic research for ophthalmoplegia-intellectual disability-lingua scrotalis syndrome has been reported in the published literature.
Phenotype severity distribution: 7 very common features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for ophthalmoplegia-intellectual disability-lingua scrotalis syndrome.
109 publications have been identified in PubMed for ophthalmoplegia-intellectual disability-lingua scrotalis syndrome. Research spans Review / Meta-Analysis (71%), Basic Science / Preclinical (16%), and Epidemiology / Natural History (5%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 77 | 71% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:51 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Eyes |
3 |
Ptosis, Abnormality of retinal pigmentation, Oculomotor nerve palsy |
Head and neck | 1 | Facial palsy |
Laboratory research |
17 |
16% |
Disease patterns and progression | 5 | 5% |
Patient case studies | 4 | 4% |
Other research | 2 | 2% |
Testing and diagnosis research | 2 | 2% |
Clinical study results | 1 | 1% |
New treatment approaches | 1 | 1% |
Buel KL (2026). [PMID: 41569909](https://pubmed.ncbi.nlm.nih.gov/41569909/). *FP Essent*. [Review / Meta-Analysis]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Borojeni S (2025). [PMID: 40546148](https://pubmed.ncbi.nlm.nih.gov/40546148/). *Rev Prat*. [Review / Meta-Analysis]
Cornejo-Sanchez DM (2025). [PMID: 40055553](https://pubmed.ncbi.nlm.nih.gov/40055553/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Walther LE (2025). [PMID: 40192781](https://pubmed.ncbi.nlm.nih.gov/40192781/). *HNO*. [Review / Meta-Analysis]
Brokke KE (2025). [PMID: 40634186](https://pubmed.ncbi.nlm.nih.gov/40634186/). *Br J Anaesth*. [Review / Meta-Analysis]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Pena C (2025). [PMID: 40146047](https://pubmed.ncbi.nlm.nih.gov/40146047/). *Minerva Med*. [Review / Meta-Analysis]